EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.

View source ↗

Summary

Xtandi (enzalutamide) has been authorised in the EU for prostatic neoplasms by Astellas Pharma Europe B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 28/07/2026